Results 1 to 10 of about 1,124,319 (216)

Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience [PDF]

Journal of International Medical Research
Objective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been ...
ılkay Cinar
doaj   +2 more sources

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

Molecules, 2021
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers.
Nichole E. M. Kaufman, Simran Dhingra, Seetharama D. Jois, Maria da Graça H. Vicente   +3 more
doaj   +1 more source

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations

Romanian Journal of Internal Medicine, 2022
Introduction: EGFR targeted therapies, have been proved beneficial for patients with HCC, nevertheless additional research on EGFR immunoexpresion and EGFR mutations is still needed, especially in population in which it has not been done yet.
Nikolova Dafina, Trajkovska Meri, Trpcevska Emilija Nikolovska, Eftimov Aleksandar, Jovanovik Rubens, Janevska Vesna   +5 more
doaj   +1 more source

Metastatic Trends in Breast Cancer According to Molecular Subtypes, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2neu Status

Journal of Medical Sciences and Health, 2022
Background : Breast cancer molecular subtypes have been established a close relationship with site specific metastasis, disease prognosis, selection of therapy and response to therapy.
Garima Uikey, Hemant Ahirwar, Rajesh Kori, Veenita YogI, Suresh Yadav, Om Prakash Singh, Rishika Saxena, Sachet Saxena   +7 more
doaj   +1 more source

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

Genome Medicine, 2017
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to ...
Leanne G. Ahronian, Ryan B. Corcoran
doaj   +1 more source

Glycosynapses: microdomains controlling carbohydrate-dependent cell adhesion and signaling

Anais da Academia Brasileira de Ciências, 2004
The concept of microdomains in plasma membranes was developed over two decades, following observation of polarity of membrane based on clustering of specific membrane components.
Senitiroh Hakomori
doaj   +1 more source

Characterization and endocytic internalization of Epith-2 cell surface glycoprotein during the epithelial-to-mesenchymal transition in sea urchin embryos

Frontiers in Endocrinology, 2013
The epithelial cells of the sea urchin Hemicentrotus pulcherrimus embryo express an Epith-2, uncharacterized glycoprotein, on the lateral surface.
Norio eWakayama, Tomoko eKatow, Hideki eKatow   +2 more
doaj   +1 more source

Amphiregulin/epidermal growth factor receptor/hypoxia-inducible factor-1α pathway regulates T helper 9 and T cytotoxic 9 cell response in adult patients with infectious mononucleosis

Biomolecules & Biomedicine, 2023
Amphiregulin (AREG)/epidermal growth factor receptor (EGFR) signaling induces hypoxia-inducible factor-1α (HIF-1α), leading to promotion of T helper 9 (Th9) differentiation and anti-tumor functions.
Yu Li, Lan Li, Weihua Zhang, Ying Gao
doaj   +1 more source

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Journal of Medical Case Reports, 2020
Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations.
Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda   +8 more
doaj   +1 more source

Functions of fibroblast growth factors and their receptors [PDF]

Current Biology, 1995
Fibroblast growth factors were first characterized twenty years ago as mitogens of cultured fibroblasts. Despite a wealth of data from experiments in vitro, insights have begun to emerge only recently on the normal function of these growth factors in mice and humans, as a result of studies of natural and experimental mutations in the factors and their ...
Wilkie, A, Morriss-Kay, G, Jones, E, Heath, J   +3 more
openaire   +3 more sources